8-K Announcements
6Material company update
Mar 4, 2025·SEC
Material company update
Feb 28, 2025·SEC
Material company update
Jan 8, 2025·SEC
Syros Pharmaceuticals, Inc.(SYRS)Earnings, Financials & Key Ratios
SYRS•NASDAQ
$0.00
Price updated Jul 6, 2026
AboutSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$10M-33.2%
- EBITDA-$127M+4.6%
- Net Income-$165M-73.9%
- EPS (Diluted)-5.81+22.4%
- Gross Margin77.33%-3.4%
- EBITDA Margin-1275.52%-42.8%
- Operating Margin-1298.19%-42.2%
- Net Margin-1656.34%-160.4%
- ROE-227.95%-156.4%
SYRS Price & Volume
Syros Pharmaceuticals, Inc. (SYRS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Capacity
Investment Thesis • Updated 2024Q3
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
Key Thesis Takeaways
- Syros Pharmaceuticals faces a precarious financial outlook characterized by a complete cessation of revenue over the last three quarters and a rapid erosion of shareholder equity to negative $11.1 million as of 2024Q3.
- The company's heavy reliance on milestone-based income creates significant volatility, while persistent quarterly R&D expenditures exceeding $20 million continue to drain liquidity.
- Investors should remain cautious as the firm's $60.2 million debt load and lack of recurring revenue streams necessitate potential dilutive financing to sustain the SELECT-MDS clinical program.
Verdict Logic
Negative: The company's fundamental viability is challenged by the combination of zero recurring revenue and a cash burn rate that has reduced the cash balance to $58.3 million as of 2024Q3.
SYRS Growth Metrics
Syros Pharmaceuticals, Inc. (SYRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years37.12%
3 Years-13.01%
TTM-90.54%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-53.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-32.68%
Return on Capital
10 Years-67.75%
5 Years-66.8%
3 Years-69.44%
Last Year-74.73%
Peers Comparison
Key metrics vs top competitors for Syros Pharmaceuticals, Inc. (SYRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.00 | $2.68K | — | -33.23% | -1656.34% | -227.95% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $29.94 | $3.48B | -34.41 | 48.29% | -188.15% | -41.54% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — |
Compare SYRS vs Peers
Syros Pharmaceuticals, Inc. (SYRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYRS SEC Filings & Documents
Syros Pharmaceuticals, Inc. (SYRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SYRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SYRS Frequently Asked Questions
Syros Pharmaceuticals, Inc. (SYRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Syros Pharmaceuticals, Inc.'s revenue?
Syros Pharmaceuticals, Inc. (SYRS) reported $0.4M in revenue for fiscal year 2023.
How fast is Syros Pharmaceuticals, Inc. growing?
Syros Pharmaceuticals, Inc. (SYRS) saw revenue decline by 33.2% over the past year.
Is SYRS profitable?
Syros Pharmaceuticals, Inc. (SYRS) reported a net loss of $97.8M for fiscal year 2023.
Dividend & Returns
What is SYRS's return on equity?
Syros Pharmaceuticals, Inc. (SYRS) has a return on equity (ROE) of -227.9%. Negative ROE indicates the company is unprofitable.
What is Syros Pharmaceuticals, Inc.'s free cash flow?
Syros Pharmaceuticals, Inc. (SYRS) had negative free cash flow of $100.1M in fiscal year 2023, likely due to heavy capital investments.